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An international group of 22 liver cancer experts from 18 institutions met in Miami, Florida
to discuss the optimal utilization of proton beam therapy (PBT) for primary and metastatic
liver cancer. There was consensus that PBT may be preferred for liver cancer patients
expected to have a suboptimal therapeutic ratio from XRT, but that PBT should not be
preferred for all patients. Various clinical scenarios demonstrating appropriateness of PBT
vs. XRT were reviewed.
Keywords: proton therapy, liver cancer, hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), liver
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Radiation therapy (RT) for liver cancer has become increasingly utilized as technological
advancements have permitted highly conformal delivery of even ablative doses. Although RT is
most commonly delivered using photons (x-rays), protons may also be considered.
In contrast to an x-ray beam, there is little to no exit dose distal to the target in a proton
beam, thereby reducing low and moderate doses to normal organs. Although the clinical benefit
of proton beam therapy (PBT) over x-ray therapy (XRT) has been proposed for some liver cancer
patients, there is a lack of consensus to guide decision making regarding utilization of PBT.
Important clinical considerations for PBT selection, however, have become better understood in
recent years (1).
In January 2018, a group of 22 experts from 18 institutions across North America, Europe,
and Asia congregated in Miami, Florida to discuss the role of PBT for liver cancer. Participants
included thought leaders from radiation oncology, medical physics, interventional radiology,
surgical oncology, and biostatistics. With the intent of conducting a balanced discussion,
approximately half had PBT experience while the remainder purposefully did not. The conference
goals included: (1) clarifying the role of PBT vs. XRT for liver cancer; (2) reaching consensus
about clinical scenarios for which PBT provides the most significant benefit vs. XRT for liver
cancer patients; and (3) identifying barriers to broader adoption of PBT for liver cancer.
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To address each of these goals the conference included interactive
presentations, treatment plan comparisons, and surveys. The
same survey questions were asked just prior to and then
again immediately upon conclusion of the conference using an
anonymous polling system (Table 1).
NORMAL LIVER TOLERANCE
The participants established that a primary rationale for PBT
is sparing uninvolved liver. As a parallel functioning organ, the
liver is tolerant of high dose delivered to a limited volume,
presuming adequate sparing of uninvolved liver and appropriate
baseline liver function (2). Minimizing both mean liver dose
(MLD) and the volume of uninvolved liver receiving at least low
dose should be of extreme importance for any liver-directed RT.
This is underscored by the endorsement that prescription dose
reduction be considered, as needed, to achieve appropriately low
liver dose while still aiming to prescribe the highest possible safe
dose. All agreed that PBT should be considered if MLD and low
dose liver constraints cannot be achieved with XRT.
There was broad agreement that a certain absolute reduction
in normal liver dose would not have the same clinical significance
for all patients because the probability of radiation-induced
liver disease (RILD) is also related to various clinical factors
like baseline liver function. For example, a small reduction
in MLD with PBT may be clinically meaningful for a patient
with Child Pugh (CP)-B8 cirrhosis whereas it is less likely to
be for a patient with CP-A5 cirrhosis. While normal tissue
complication probability (NTCP) models are not routinely used
in the management of liver cancer patients, it was agreed that
such modeling could help considerably in prioritizing patients
for PBT.
ROLE OF RADIATION THERAPY FOR
LIVER CANCER
There was unanimous agreement that both XRT and PBT are not
experimental for treating primary or metastatic liver cancer, and
that both are effective in achieving high rates of local control with
acceptable toxicity.
On the pre-conference survey the overwhelming majority
indicated that access to PBT would benefit their institution’s
liver cancer program based predominantly on the recognition
of unsatisfactory clinical outcomes after XRT in some patients,
particularly those with HCC and unfavorable baseline
characteristics such as large tumor and suboptimal baseline
liver function. All participants on the post-conference survey
responded that PBT would benefit at least some liver patients at
their institution, largely due to better understanding of how to
overcome perceived barriers to liver PBT (e.g., target motion,
range uncertainty) and the application of PBT for selected
patients with non-HCC liver cancer.
There was an overarching belief that reduced normal organ
dose achieved with PBT is not clinically relevant for all liver
cancer patients, and that careful consideration should be given
to which patients should be prioritized for PBT.
CLINICAL DECISION MAKING AND
PATIENT PRIORITIZATION FOR PBT
The majority of the conference was devoted to reviewing clinical
factors that indicate a high probability of benefit from PBT.
Conversation focused on patients with hepatocellular carcinoma
(HCC), among whom hypofractionated PBT has been extensively
evaluated with remarkable long-term outcomes (3).
Hypofractionated XRT outcomes for HCC have also been
excellent, especially for patients with well-compensated cirrhosis
(e.g., CP-A), smaller tumor size (e.g., ≤3–5 cm), limited number
of tumors (e.g., 1–3), and no prior liver RT (4).
There was consensus that PBT should be more strongly
considered for HCC patients with the following:
• At least CP-B cirrhosis
• High tumor-to-liver ratio
• Larger tumor size
• Smaller uninvolved liver volume
• Higher number of tumors
• Prior RT to the liver.
After much discussion it was determined that consensus could
not be reached on absolute threshold criteria for these based on
the published literature, and that best clinical judgment should be
used until data are published to provide more objective guidance.
Moreover, there was uniform agreement that the presence of
multiple factors for RILD would further strengthen the rationale
for PBT (1).
The appropriateness of treating CP-B cirrhosis patients with
XRT was next debated. Some felt strongly that XRT is feasible
for CP-B patients if using an individualized adaptive strategy (5)
although most indicated that they do not routinely offer XRT to
all CP-B patients because of concerns about potentially severe
toxicity (6, 7).
To illustrate what dosimetric differences can be achieved in
various scenarios (Table 2), PBT and XRT plans were created
for 5 cases (A-E) by institutions represented at the conference
according to the Radiation Therapy Oncology Group (RTOG)
1112 protocol that requires a prescription of 50Gy in 5 fractions
based on the achievableMLD, with tiered de-escalation as needed
to satisfy MLD constraints (Figure 1). The results were blinded
until convening in Miami. As expected, both PBT and XRT plans
were able to achieve excellent liver sparing for the smallest tumor
(case A), and there was complete agreement that XRT should be
preferred unless in the context of at least CP-B cirrhosis. The
appropriateness of PBT was amplified with increasing tumor-
to-liver ratio compared to either tumor size or uninvolved
liver volume alone (Figure 2). The highest MLD and the most
extensive prescription de-escalations in XRT plans occurred for
case B, which did not have the largest tumor volume although
featured the smallest uninvolved liver volume and highest
tumor-to-liver ratio. Assuming well-compensated cirrhosis most
considered XRT to be appropriate for cases C and D. Finally,
while case E could be treated with PBT nearly all believed
that other liver-directed therapies may be more appropriate.
To emphasize that point, the participant surveys indicated that
most believed radioembolization or chemoembolization to be
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TABLE 1 | Pre- and post-conference participant survey results.
All survey questions Pre-conference (%) Post-conference (%)
General and proton specific Yes No Not sure Yes No Not sure
Is radiation therapy an effective treatment for
liver cancers?
100 0 0 100 0 0
Would you consider access to proton therapy a
benefit to your liver cancer program?
87 7 6 100 0 0
Should proton therapy be recommended for all
liver cancer patients in place of x-ray therapy?
7 80 13 15 85 0
It is reasonable to consider proton therapy for
the treatment of unresectable non-metastatic
cholangiocarcinoma?
94 0 6 93 0 7
Proton therapy should be considered to treat
liver metastases in patients with liver-only or
liver-dominant disease
72 17 11 71 22 7
Radioembolization or chemoembolization
should be preferred over proton therapy for
management of some patients with extensive
multifocal liver cancers?
67 33 0 86 15 7
Is the complexity of proton therapy treatment
planning a barrier to proton therapy adoption?
29 65 6 21 65 14
Is respiratory motion a major obstacle for broad
adoption of proton therapy for liver cancers?
33 50 17 21 65 14
Is proton therapy range uncertainty a major
obstacle for broad adoption of proton therapy
for liver cancers?
22 61 17 14 86 0
Is the lack of adequate image guidance a major
obstacle for the broad adoption of proton
therapy for liver cancers?
6 50 44 50 43 7
Is the cost of proton therapy a barrier to broad
adoption?
94 6 0 100 0 0
Randomized data should be required for broad
adoption of proton therapy for liver cancer
patients
41 59 0 36 64 0
TABLE 2 | Tumor and liver characteristics of 5 cases planned with X-ray therapy (XRT) and proton beam therapy (PBT).
Case Involved lobe(s) Involved
segment(s)
Total number of
tumors
Largest tumor
diameter (cm)
Total tumor
volume (cc)
Total uninvolved
liver volume (cc)
Tumor-to-liver
ratio x 100
A Right 8 1 5 40.7 1876.2 2.2
B Right 6, 7, 8 1 10 216.5 1239.7 17.5
C Right 5, 6 1 13 365.8 2453 14.9
+ main PVTT + main PVTT + main PVTT
D Right 6, 7 3 3, 4, 8 89.3 2722 3.3
E Left 2, 3, 4 5 Left Lobe: 4, 8 120 2697 4.5
Right 6 Right Lobe: 3, 4, 8
PVTT, portal vein tumor thrombus.
preferred for at least some patients with extensive liver tumor
burden, particularly those with numerous bilobar lesions that
could not be appropriately treated with either PBT or XRT while
meeting normal liver and target volume constraints.
The participants believed that treatment planning
comparisons should be considered to assist in clinical decision
making between PBT and XRT although should not be required
when the expected benefit from PBT is especially high.
PBT FOR CHOLANGIOCARCINOMA AND
LIVER METASTASES
As opposed to HCC patients in which PBT is primarily intended
to reduce the probability of liver dysfunction vs. XRT, emerging
data suggest that PBT may be beneficial for selected patients
with unresectable intrahepatic cholangiocarcinoma (IHC) or
metastatic liver disease with the rationale being that tumor dose
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FIGURE 1 | Prescription de-escalation based on achieved mean liver dose (MLD) as per RTOG 1112.
FIGURE 2 | Achieved prescription dose and mean liver dose (MLD) for x-ray vs. proton treatment plans.
escalation to an ablative level may not be achievable with XRT
while also respecting normal liver constraints for some patients
(e.g., larger and/or numerous lesions) (8, 9). The importance of
achieving an ablative tumor dose, which improves tumor control
and even potentially overall survival compared to lower doses,
has been demonstrated in numerous publications (10, 11).
Based on these data, most participants (70%) believed that
PBT is reasonable to consider for selected patients with liver
metastasis while an even larger majority (93%) believed that
it is reasonable to treat unresectable non-metastatic IHC.
Still, all patients should be discussed in a multidisciplinary
manner with respect to all potential management options.
Furthermore, it was recommended that PBT be considered
in the context of potentially curative treatment for liver-
only or liver-dominant disease. There was strong support for
enrolling such patients to clinical trials whenever available to
better define patient subsets that achieve the most meaningful
clinical benefit.
Frontiers in Oncology | www.frontiersin.org 4 May 2019 | Volume 9 | Article 457
Chuong et al. Liver Proton Therapy Consensus
BARRIERS TO PBT UTILIZATION
The cost of PBT was considered by nearly all as one of the most
restrictive and significant barriers to expanding PBT utilization
for liver cancer. Frequent challenges with insurance approval for
liver PBT were also mentioned despite the inclusion of HCC as
a Group 1 indication (highest recommendation) in the ASTRO
Model Policy for Proton Beam Therapy (12).
On the pre-conference survey over 40% indicated that they
were not sure whether image guidance was a barrier to liver
PBT,most likely reflecting that approximately 50% of participants
had not treated patients with PBT and were unfamiliar with
image guidance capabilities at most PBT centers. During the
conference some voiced concern that PBT image guidance has
historically been subpar when compared to XRT image guidance
capabilities. However, there was strong sense of confidence
especially among those familiar with PBT that PBT imaging
techniques are currently improving including through more
widespread availability of high-quality cone-beam computed
tomography (CT) scans.
Commonly perceived barriers related to treatment planning
were surprisingly not of concern to most. Although there are
potentially severe consequences due to the interplay effect when
treating moving targets, almost two-thirds felt that respiratory
motion was not a major obstacle even if using pencil beam
scanning (compared to passive scattering, which is more robust).
Treating moving targets was considered feasible if employing
effective treatment planning strategies (e.g., repainting, 4-
dimensional robust optimization, robust beam angle selection,
increased fractionation) combined with motion management
techniques. It was noted that such strategies have been employed
for decades with excellent long-term outcomes (13). Still, it
should be noted that the majority of published clinical outcomes
have been achieved with passive scattering and that additional
study is needed with respect to pencil beam scanning. The vast
majority (86%) similarly did not feel that distal range uncertainty
restricts high quality liver PBT if using appropriate treatment
planning techniques.
Lastly, nearly two-thirds believed that randomized data
should not be an absolute requirement to justify PBT for
liver cancer. Still, many agreed that randomized trials should
be pursued, especially to improve our understanding of
which patient subgroups should be prioritized for PBT. In
the meantime, the extensive published observational data
for liver cancer should be considered sufficient to justify
recommending PBT.
CONCLUSIONS
The Miami conference successfully brought together a diverse
international group of experts who reached consensus that PBT
is expected to dramatically improve clinical outcomes for some,
but not all liver cancer patients compared to XRT. Future studies
should focus on identifying which patient subgroups achieve
the greatest clinical advantage from PBT to guide treatment
decision making.
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